Zobrazeno 1 - 10
of 179
pro vyhledávání: '"Hiroyuki, Kunishima"'
Autor:
Mami Ueta, Alton Cao, Michio Murakami, Hana Tomoi, Stuart Gilmour, Keiko Maruyama-Sakurai, Yoshihiro Takayama, Yoshitake Takebayashi, Masahiro Hashizume, Rauniyar Santosh Kumar, Hiroyuki Kunishima, Wataru Naito, Tetsuo Yasutaka, Satoshi Kaneko, Hiroaki Miyata, Shuhei Nomura
Publikováno v:
Vaccine: X, Vol 19, Iss , Pp 100528- (2024)
Objectives: This study aims to investigate the factors influencing parental willingness in COVID-19 vaccination for children in Japan in light of the introduction of pediatric vaccines. Methods: An online survey was conducted in February 2022, coinci
Externí odkaz:
https://doaj.org/article/aef6404e170d4833b8d86248e29cbfe7
Autor:
Kenichi Nakazono, Hiroki Saito, Ayaka Ohkubo, Hidetaka Onodera, Haruaki Wakatake, Yuta Katsuta, Junpei Tada, Hiroyuki Kunishima, Takashi Matsuzaki
Publikováno v:
IDCases, Vol 37, Iss , Pp e02035- (2024)
The area under the concentration-time curve (AUC)/minimum inhibitory concentration (MIC) – guided approach is recommended for vancomycin therapeutic drug monitoring in severe methicillin-resistant Staphylococcus aureus (MRSA) infection. However, ev
Externí odkaz:
https://doaj.org/article/eade2f422cb54e1e8f8a506ac33c267e
Autor:
Hidetoshi Nomoto, Hiroki Saito, Masahiro Ishikane, Yoshiaki Gu, Norio Ohmagari, Didier Pittet, Hiroyuki Kunishima, Benedetta Allegranzi, Masaki Yoshida
Publikováno v:
Antimicrobial Resistance and Infection Control, Vol 11, Iss 1, Pp 1-10 (2022)
Abstract Background Infection prevention and control (IPC) measures in Japan are facilitated by a financial incentive process at the national level, where facilities are categorized into three groups (Tier 1, Tier 2, or no financial incentive). Howev
Externí odkaz:
https://doaj.org/article/c662c01ffd8c4a588ea5ebc5e9b6d1b9
Autor:
Mariko Mouri, Mitsuru Imamura, Shotaro Suzuki, Tatsuya Kawasaki, Yoshiki Ishizaki, Keiichi Sakurai, Hiroko Nagafuchi, Norihiro Matsumura, Marina Uchida, Takayasu Ando, Kohei Yoshioka, Seido Ooka, Takahiko Sugihara, Hiroshi Miyoshi, Masaaki Mori, Tomoyuki Okada, Masao Yamaguchi, Hiroyuki Kunishima, Motohiro Kato, Kimito Kawahata
Publikováno v:
Allergology International, Vol 71, Iss 4, Pp 512-519 (2022)
Background: The mechanism of allergic reactions to COVID-19 mRNA vaccines has not been clarified. Polyethylene glycol (PEG) is a potential antigen in the components of vaccines. However, there is little evidence that allergy after COVID-19 mRNA vacci
Externí odkaz:
https://doaj.org/article/487d8d69a5f24176855c9716279742e8
Autor:
Tomonori Takano, Hayami Kudo, Shuhei Eguchi, Asami Matsumoto, Kentaro Oka, Yukitaka Yamasaki, Motomichi Takahashi, Takuro Koshikawa, Hiromu Takemura, Yuka Yamagishi, Hiroshige Mikamo, Hiroyuki Kunishima
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 13 (2023)
IntroductionAntifungal agents are not always efficient in resolving vulvovaginal candidiasis (VVC), a common genital infection caused by the overgrowth of Candida spp., including Candida albicans, or in preventing recurrent infections. Although lacto
Externí odkaz:
https://doaj.org/article/fa828455c17544febc7fe808b34e6190
Autor:
Megumi Adachi, Michio Murakami, Daisuke Yoneoka, Takayuki Kawashima, Masahiro Hashizume, Haruka Sakamoto, Akifumi Eguchi, Cyrus Ghaznavi, Stuart Gilmour, Satoshi Kaneko, Hiroyuki Kunishima, Keiko Maruyama-Sakurai, Yuta Tanoue, Yoshiko Yamamoto, Hiroaki Miyata, Shuhei Nomura
Publikováno v:
SSM: Population Health, Vol 18, Iss , Pp 101105- (2022)
Understanding COVID-19 risk perception may help inform public health messaging aimed at encouraging preventive measures and improving countermeasures against the pandemic. We conducted an online survey of 29,708 Japanese adults in February 2021 and e
Externí odkaz:
https://doaj.org/article/5d96fbb3a25e482b828b198b3f8c959b
Autor:
Daisuke Yoneoka, Takayuki Kawashima, Yuta Tanoue, Shuhei Nomura, Keisuke Ejima, Shoi Shi, Akifumi Eguchi, Toshibumi Taniguchi, Haruka Sakamoto, Hiroyuki Kunishima, Stuart Gilmour, Hiroshi Nishiura, Hiroaki Miyata
Publikováno v:
Journal of Epidemiology, Vol 30, Iss 8, Pp 362-370 (2020)
Background: The World Health Organization declared the novel coronavirus outbreak (COVID-19) to be a pandemic on March 11, 2020. Large-scale monitoring for capturing the current epidemiological situation of COVID-19 in Japan would improve preparation
Externí odkaz:
https://doaj.org/article/bc186bb4253c4b10b54ebcff842a79cb
Autor:
Yukitaka Yamasaki, Seido Ooka, Shin Matsuoka, Hayato Tomita, Masanori Hirose, Tomonori Takano, Shotaro Suzuki, Mitsuru Imamura, Hiroshi Handa, Hiroki Nishine, Mumon Takita, Ayu Minoura, Kenichiro Morisawa, Takeo Inoue, Masamichi Mineshita, Kimito Kawahata, Hiromu Takemura, Shigeki Fujitani, Hiroyuki Kunishima
Publikováno v:
PLoS ONE, Vol 17, Iss 11, p e0276738 (2022)
Presently, coronavirus disease-19 (COVID-19) is spreading worldwide without an effective treatment method. For COVID-19, which is often asymptomatic, it is essential to adopt a method that does not cause aggravation, as well as a method to prevent in
Externí odkaz:
https://doaj.org/article/c8fd494e708b4890bf05d2c99f04e1bb
Autor:
Daisuke Yoneoka, PhD, Akifumi Eguchi, PhD, Shuhei Nomura, PhD, Takayuki Kawashima, PhD, Yuta Tanoue, PhD, Michio Murakami, PhD, Haruka Sakamoto, PhD, Keiko Maruyama-Sakurai, MPH, Stuart Gilmour, PhD, Shoi Shi, PhD, Hiroyuki Kunishima, PhD, Satoshi Kaneko, PhD, Megumi Adachi, BN, Koki Shimada, PhD, Yoshiko Yamamoto, PhD, Hiroaki Miyata, PhD
Publikováno v:
The Lancet Regional Health. Western Pacific, Vol 18, Iss , Pp 100330- (2022)
Summary: Background: Optimizing media campaigns for those who were unsure or unwilling to take coronavirus disease (COVID-19) vaccines is required urgently to effectively present public health messages aimed at increasing vaccination coverage. We pro
Externí odkaz:
https://doaj.org/article/3474f9026fc3422a921789f1a0863385
Autor:
Kazuhiro Kamata, Kazuaki Jindai, Nao Ichihara, Hiroki Saito, Hideaki Kato, Hiroyuki Kunishima, Ayumi Shintani, Osamu Nishida, Shigeki Fujitani
Publikováno v:
Journal of Intensive Care, Vol 9, Iss 1, Pp 1-3 (2021)
Abstract REMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now j
Externí odkaz:
https://doaj.org/article/8464a5ec628e4ab6bed5032b72584469